LOCAL biotechnology company Phylogica has announced a new discovery of proprietary compounds that protect brain cells under conditions that simulate stroke.
The compounds, called phylomers, are small fragments of protein that act by preventing the inappropriate interactions of proteins that cause disease, Phylogica says.
While the rate of stroke is on the rise, there is currently no effective therapy for prevention of stroke-related brain damage.
The company estimates the market for stroke treatments will reach $US5.4 billion by 2006.
Phylogica recently completed its initial public offering in which it raised $5 million for the development of its phylomer lead drug compounds.
© Business News 2017. You may share content using the tools provided but do not copy and redistribute.